Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Advances in Therapy.
Times cited: 136
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
European journal of cancer (Oxford, England : 1990).
Times cited: 33
- Perspective on...the new PSA screening recommendations. ONCOLOGY. 2011 Academic Article GET IT